Physician profile
Stephen Yoelson
NPI 1306856463
$5,825.03
in general payments reported to CMS, 2019-2025
19 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,422 · 2020: $253 · 2021: $240 · 2022: $1,195 · 2023: $831 · 2024: $778 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,715.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,836.04 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,224.06 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $929.73 | 2022-2025 | |
| Pfizer INC. | $346.63 | 2019-2020 | |
| Abbvie INC. | $303.58 | 2023-2025 | Vraylar |
| Allergan, INC. | $295.54 | 2019-2020 | |
| Amgen INC. | $181.51 | 2019 | |
| Lilly USA, LLC | $139.53 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $133.99 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.00 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $68.29 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.07 | 2019 | |
| Amarin Pharma, INC. | $45.63 | 2019 | |
| Glaxosmithkline, LLC. | $43.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.77 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $26.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.15 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Yoelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.